Siemens Healthineers Secures Six FDA Clearances for AI-Powered Imaging as Restructuring Pressures Mount

FDA clears six Artis Vision configurations with Optiq AI. Imaging segment grows 6% amid Diagnostics woes. CEO pushes separation; stock near 52-week low at €34.

The diagnostics and imaging group has won regulatory approval in the United States for a slate of new interventional radiology systems, offering a flicker of operational momentum against a backdrop of corporate upheaval and a share price languishing near its 52-week low. The US Food and Drug Administration has cleared six configurations of the Artis Vision platform, including floor-mounted, biplane and robotic variants, as well as specific models under the Artis icono.explore and Artis genio brands. At the heart of the systems is the Optiq AI imaging chain, which uses artificial-intelligence algorithms to analyse visual data in real time, boosting precision during minimally invasive procedures while helping control radiation doses for both patients and staff.

The fresh approvals are a timely fillip for the Imaging segment, which has become the group’s most reliable earnings engine. In the latest quarter, Imaging posted revenue growth of roughly 6% and an adjusted operating margin of 22.4%, partly offsetting the drag from the troubled Diagnostics division. Chief Executive Bernd Montag is pushing ahead with a formal process to separate Diagnostics, a unit that has been hit hard by structural market changes in China that are squeezing margins. The company has cut its full-year revenue growth forecast to between 4.5% and 5%, and options being explored for Diagnostics range from a sale to an initial public offering.

The broader restructuring goes beyond the portfolio. Siemens Healthineers is also moving to sever its financial umbilical cord from parent Siemens AG. Shareholders will vote on a direct demerger at the annual general meeting in February 2027, with the parent planning to reduce its current 67% stake to below 20% over the medium term. That independence carries a price: the parent currently guarantees loans of up to €13.9bn, a backstop that will disappear after the split. A consortium of banks is already lined up to provide future refinancing, while net debt stood at €13.2bn at the end of March.

In the C-suite, the shake-up continues. Martin Stumpe, a former Google Brain developer, will take over as Chief Technology Officer in June 2026, tasked with driving the company’s AI strategy in healthcare. He replaces Peter Schardt, who is leaving along with three other senior executives. The leadership changes come as the group seeks to embed artificial intelligence more deeply across its product line, from the newly cleared Artis systems to its broader imaging and therapy portfolio.

Investors, however, have yet to reward any of these moves. The stock closed at €34.00 on Wednesday and edged up to €34.42 on Thursday, a whisker above the session low of €33.50 that marks the bottom of the 52-week range. Since the start of the year, the shares have shed roughly 22–23% of their value, a slide driven by the prolonged Diagnostics weakness in China and higher input costs. The company has flagged rising expenses for memory chips and logistics, which are adding to the earnings headwinds.

Despite the near-term gloom, the underlying earnings potential remains intact. Excluding currency and tariff effects, adjusted earnings per share growth would have been about 16% in the second quarter, when group revenue reached €5.7bn. Analysts see the possibility of 5–7% annual growth in adjusted profits from the core business, even without a swift recovery in China. The new FDA clearances give the Imaging unit another weapon in the fight for market share, and the group’s ability to scale the commercial rollout of the Artis platform over the current financial year will be crucial in creating a counterweight to the cost pressures and restructuring noise.